andinpandemicsituations.VLPshavebeenproducedsuccessfull
thetimelysupplyofinfluenzavaccineforbothseasonalepidemic
conventionalinfluenzavaccines42,43.Thisisacriticaladvantagefo
than half the time (2â€“3 months) required for the manufacture o
rHA are harvested and purified (Fig. 1). This process requires les
thevaccineareinsertedintotheBEVS,fromwhichhighyieldso
sequences from the wild-type strains selected for inclusion i
nated eggs or mammalian cell-lines. Instead, HA geneti
candidate vaccine viruses selected for robust growth in embryo
insect cells does not depend on the generation of reassortan
egg-free. Like other recombinant vaccines, expression of HA i
RIV4 is one of only two available influenza vaccines that ar